Louis Lange

Cardiogen Sciences, Inc. is a biotechnology company that develops and offers gene therapy solutions for orphan-inherited arrhythmogenic diseases. The company was founded by Louis G. Lange in 2014 and is headquartered in Palo Alto, CA.

VantagePoint Management, Inc. (VantagePoint) is a venture capital firm founded in 1996 by Alan Edward Salzman, James D. Marver. The firm is headquartered in Santa Barbara, California with additional office in Beijing, China.

Institute for Systems Biology operates as a nonprofit biomedical research organization. It develops a systems approach to characterize, predict, and manipulate state transitions in biological system. The company was founded by Leroy E. Hood, Ruedi Aebersold and Alan Aderem in 2000 and is headquartered in Seattle, WA.

Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA.

Asset Management Ventures LLC (AMV) is a venture capital subsidiary of Asset Management Co. founded in 1965 by Franklin Pitcher Johnson. The firm is headquartered in Palo Alto, California.

Maverix Biomics, Inc. provides cloud-based platform to manage, analyze and visualize genomic data. It also builds communities of discovery and place its data in context with the latest public data from the full spectrum of life, including human, plant, animal or microbial organisms. The company was founded by David Mandelkern, Todd Michael Johnson Lowe and Patricia Pak Lee Chan in 2010 and is headquartered in San Mateo, CA.

Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA.

Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA.

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA.

Teon Therapeutics, Inc. operates as a pharmaceutical company. It focuses on cancer immunotherapy. The company was founded by Yao Lina, Fan Peidong, Elfaith Elzein, and Liiu Jiwen in March 2018 and is headquartered in Redwood City, CA.

DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister.

Epiphany Technology Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 28, 2020 and is headquartered in Burlingame, CA.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

BioPlus Acquisition Corp. is an early stage blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying an opportunity in the life sciences industry. The company was founded on February 11, 2021 and is headquartered in New York, NY.

Enterprise 4.0 Technology Acquisition Corp. is a blank check company, which engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on May 3, 2021 and is headquartered in Palo Alto, CA.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.